Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 7;7:7371. doi: 10.1038/s41598-017-07044-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Bone mineral density is enhanced in meclozine-treated Fgfr3 ^ach mice. (A) Representative reconstructed micro-CT images of the distal femur at the end of treatment revealed that metaphyseal bone mineral density was increased after meclozine treatment. Upper panels show 2D images of the distal femur and lower panels show 3D images of metaphyseal trabecular bone. (B) The average relative ratio of bone mineral density (BMD) was increased after meclozine treatment while there were no statistical differences in bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp). Relative values were calculated based on those of untreated Fgfr3 ^ach mice. Mean and SD are indicated. Statistical significance was analyzed by the unpaired t test for each dose of meclozine-treated Fgfr3 ^ach mice (n = 6 and 5 for 1 and 2 mg/kg/day of meclozine, respectively) or untreated wild-type mice (n = 10) versus untreated Fgfr3 ^ach mice (n = 9).